title: The selective μ opioid receptor antagonist β-funaltrexamine attenuates methamphetamine-induced stereotypical biting in mice.
abstract: We investigated whether pretreatment with opioid receptor antagonists affected methamphetamine (METH)-induced stereotypy in mice. Pretreatment of male ICR mice with naloxone, a relatively non-selective opioid receptor antagonist, significantly attenuated the total incidence of METH-induced stereotypical behavior compared with saline vehicle-pretreated subjects. Furthermore, the distribution of METH-induced stereotypical behavior was affected by naloxone administration. Thus, METH-induced stereotypical sniffing and persistent locomotion were significantly increased by naloxone treatment while stereotypical biting was reduced. One way to interpret this pattern of effects is that pretreatment with naloxone appeared to produce a shift in the dose-response curve for METH. Thus, while the more intense forms of oral-facial stereotypies were reduced, increased persistent locomotion was observed in mice given naloxone followed by METH. The selective μ opioid receptor antagonist β-funaltrexamine, but not nor-binaltorphimine (a κ-selective antagonist) nor naltrindole (a δ-selective antagonist), mimicked the effect of naloxone. These observations suggest that opioid receptor antagonists may attenuate METH-induced stereotypical biting in mice via μ opioid receptors, and suggest that antagonism of this system may be a potential therapeutic approach to reducing some deleterious effects of METH use and perhaps in the treatment of some forms of self-injurious behavior.
authors.affiliation: Department of Pharmacology, Hyogo College of Medicine, Hyogo 663-8501, Japan. kitanaka-hyg@umin.net
authors.forename: Junichi
authors.initials: J
authors.lastname: Kitanaka
authors.forename: Nobue
authors.initials: N
authors.lastname: Kitanaka
authors.forename: F Scott
authors.initials: FS
authors.lastname: Hall
authors.forename: George R
authors.initials: GR
authors.lastname: Uhl
authors.forename: Yuko
authors.initials: Y
authors.lastname: Fukushima
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Sawai
authors.forename: Kaname
authors.initials: K
authors.lastname: Watabe
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Kubo
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Takahashi
authors.forename: Koh-Ichi
authors.initials: K
authors.lastname: Tanaka
authors.forename: Nobuyoshi
authors.initials: N
authors.lastname: Nishiyama
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Tatsuta
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Morita
authors.forename: Motohiko
authors.initials: M
authors.lastname: Takemura
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D000697:Central Nervous System Stimulants / Q000009:adverse effects; D008297:Male; D008694:Methamphetamine / Q000009:adverse effects; D051379:Mice; D008813:Mice, Inbred ICR; D009271:Naltrexone / Q000031:analogs & derivatives* / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology*; D017450:Receptors, Opioid, mu / Q000037:antagonists & inhibitors*; D013239:Stereotyped Behavior / Q000187:drug effects*
chemical_list: D000697:Central Nervous System Stimulants; D009292:Narcotic Antagonists; D017450:Receptors, Opioid, mu; D008694:Methamphetamine; D009271:Naltrexone; C024524:beta-funaltrexamine